engleski

V617F mutation in JAK2 is associated idiopathic myelofibrosis

Most patients with polycythemia vera and half with idiopathic myelofibrosis and essential thrombocythemia have an acquired V617F mutation in JAK2. Using sensitive PCR-based methods, we genotyped 152 patients with idiopathic myelofibrosis in order to establish whether there were differences in presentation and outcome between those with and those without the mutation. V617F-positive patients had higher neutrophil and white cell counts (p=0.02) than V617F-negative patients, but other diagnostic features were comparable between the two groups. V617F-positive patients were less likely to require blood transfusion during follow-up (p=0.03). Despite this, V617F-positive patients had poorer overall survival, even after correction for confounding factors (p=0.01).

V617F Jak2; myelofibrosis; prognosis; chronic myeloproliferation

nije evidentirano